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Abstract: Malaria and Chagas disease, caused by Plasmodium spp. and Trypanosoma cruzi parasites,
remain important global health problems. Available treatments for those diseases present several
limitations, such as lack of efficacy, toxic side effects, and drug resistance. Thus, new drugs are ur-
gently needed. The discovery of new drugs may be benefited by considering the significant biological
differences between hosts and parasites. One of the most striking differences is found in the purine
metabolism, because most of the parasites are incapable of de novo purine biosynthesis. Herein,
we have analyzed the in vitro anti-P. falciparum and anti-T. cruzi activity of a collection of 81 purine
derivatives and pyrimidine analogs. We firstly used a primary screening at three fixed concentrations
(100, 10, and 1 µM) and progressed those compounds that kept the growth of the parasites < 30%
at 100 µM to dose–response assays. Then, we performed two different cytotoxicity assays on Vero
cells and human HepG2 cells. Finally, compounds specifically active against T. cruzi were tested
against intracellular amastigote forms. Purines 33 (IC50 = 19.19 µM) and 76 (IC50 = 18.27 µM) were
the most potent against P. falciparum. On the other hand, 6D (IC50 = 3.78 µM) and 34 (IC50 = 4.24 µM)
were identified as hit purines against T. cruzi amastigotes. Moreover, an in silico docking study
revealed that P. falciparum and T. cruzi hypoxanthine guanine phosphoribosyltransferase enzymes
could be the potential targets of those compounds. Our study identified two novel, purine-based
chemotypes that could be further optimized to generate potent and diversified anti-parasitic drugs
against both parasites.
Keywords: Plasmodium falciparum; Trypanosoma cruzi; purine metabolism; purine derivatives; pyrimi-
dine analogs; phenotypic assays; cytotoxicity assays
1. Introduction
Infectious diseases caused by protozoan parasites, such as malaria and Chagas disease,
remain an important global health problem, causing high morbidity and mortality in
humans. Malaria, caused by Plasmodium spp. parasites, affects more than 200 million
people worldwide, and inflicts the highest burden in Africa, mostly in children under
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five years old [1]. Amongst the five Plasmodium species that cause malaria in humans,
P. falciparum is the deadliest, and the most prevalent in Africa [1,2]. Artemisinin-based
combination therapies (ACTs) are the recommended first-line treatments against malaria [3].
However, parasite resistance against artemisinin has considerably increased, and become
widespread in the last few years [4–6].
Chagas disease, whose etiological agent is the protozoan parasite Trypanosoma cruzi,
affects more than 6 million people worldwide [7]. The disease is endemic in Latin America,
but has spread its impact to non-endemic countries due to migrations in recent decades [8].
Chemotherapeutic treatment is limited to two drugs—benznidazole (BNZ), and nifurtimox
(NFX)—which present variable efficacy at the chronic stage of the disease, along with
frequent side effects [9,10]. Since available drugs to treat these infectious diseases have
several shortcomings, the discovery of new active compounds against P. falciparum and
T. cruzi is urgently needed [11].
The increasing knowledge of the parasites’ biology, together with the availability of
their complete genomes, has made the targeted design of new compounds a promising
drug discovery strategy [12]. Exploiting biochemical and physiological differences between
parasites and hosts could contribute to the development of new drugs. One of the most
outstanding divergences between these can be found in the purine metabolism [12]. As with
other protozoan parasites, P. falciparum and T. cruzi are incapable of de novo biosynthesis
of purines. Consequently, they depend on the purine salvage pathway for development
and proliferation [13,14]. The purine salvage pathway entails transmembrane transporters
for the uptake of nucleosides/nucleobases, as well as a series of processing enzymes,
which show considerable differences between parasites and mammals—some of them not
being present in the latter. Such enzymes thus constitute very attractive chemotherapeutic
targets [15]. In this context, two different approaches have been evaluated: the inhibition
of specific enzymes, and the use of subversive substrates.
P. falciparum purine metabolism mainly relies on three enzymes: hypoxanthine-
guanine-xanthine phosphoribosyltransferase (HGXPRT), adenosine deaminase (ADA),
and purine nucleoside phosphorylase (PNP) [16]. Within the parasite, purine salvage
metabolism is funneled through hypoxanthine by the sequential actions of ADA and PNP,
prior to phosphoribosylation by HGXPRT [16]. ADA and PNP have dual catalytic speci-
ficities that allow them to use purine and methylthiopurine substrates [16]. Most reports
have focused on targeting the purine nucleoside phosphorylase (PNP) of P. falciparum as a
mechanism to disrupt two metabolic pathways by targeting just one enzyme [16], or on the
inhibition of its HGXPRT to avoid the conversion of hypoxanthine, guanine, or xanthine
into their monophosphate derivatives [17]. Those enzymes are key players in P. falciparum’s
purine metabolism, but there are others—such as guanosine-5′-monophosphate synthase
(GMPS), adenylosuccinate synthetase (ADSS), and inosine-5′-monophosphate dehydroge-
nase (IMPDH)—that are also involved [12].
The purine salvage pathway in T. cruzi includes the following relevant enzymes from a
chemotherapeutical point of view: adenine phosphoribosyl transferase (APRT), hypoxanthine-
guanine phosphoribosyltransferase (HGPRT), adenosine kinase (AK), methylthioadenosine
phosphorylase (MTAP), and nucleoside hydrolases (NHs) [12]. T. cruzi parasites salvage
hypoxanthine and guanine in preference to adenosine, which are converted to IMP and GMP
by the enzymatic activity of HGPRT [14]. In addition, hypoxanthine is the most abundant
purine base in human serum. Thus, HGPRT plays a crucial role in the survival of T. cruzi
parasites, which has made it the target chosen in most of the studies performed [18–21].
Others have screened collections of purine- or pyrimidine-based nucleosides without
focusing on a specifically targeted enzyme [22–24]. This is the strategy that has been fol-
lowed in the present work. Recently, some β-hydroxy- and β-aminophosphonate acyclonu-
cleosides have been shown to inhibit P. falciparum growth [25], while 7-deazaguanosine
compounds displayed activity against Leishmania donovani, Trypanosoma brucei, T. cruzi and
P. falciparum [26]. Similarly, purine derivatives such as tubercidin, formycin A, formycin
B, cordycepin, puromycinaminonucleoside, and allopurinol have shown to have in vitro
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anti-T. cruzi activity [24]. Moreover, allopurinol, whose active metabolite is generated by
phosphoribosylation, has even reached clinical evaluation for Chagas disease [27].
Herein, we have phenotypically evaluated the anti-P. falciparum and anti-T. cruzi
activity of a collection of 81 purine derivatives and pyrimidine analogs that were developed
via different synthetic procedures focused on the exploration of positions 6, 8, and 9 of the
purine ring (Figure 1) [28–30]. With the prioritized compounds specifically active against
each parasite, we additionally performed a computational docking study to identify their
potential targets.
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Figure 1. Chemical structures and classifications of the evaluated compounds. Letters A–E identify the five different 
chemical groups (scaffolds), while their accompanying numbers depict scaffold subgroups (see Section 4.1 for further 
details). *, indicates different chemical substituents. 
2. Results 
2.1. Primary Screening 
Upon screening the collection of 81 compounds at three concentrations (100, 10, and 
1 µM), P. falciparum growth was kept below 30% relative to the control in the presence of 
10 of the compounds at 100 µM, and also of 1 of them when evaluated at 10 µM (Table 1). 
Among those compounds, 2 belonged to group C and 8 to group D (Table S1). On the 
other hand, T. cruzi growth was kept below 30% of its control when exposed to 28 of the 
compounds at 100 µM, and also when exposed to 2 of them at 10 µM (Table 1). In contrast 
to what was observed in P. falciparum, at least one compound per group showed activity 
against T. cruzi. Indeed, 2 compounds were from group A, 2 from group B, 5 from group 
C, 17 from group D and 2 from group E (Table S2). Neither parasite exhibited growth 
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from different structural groups.
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Table 1. Number of compounds classified according to the percentage of parasite growth in the primary screening.
Parasite Growth Rate Relative to the Assay Negative Control
Compound Concentration (µM) P. falciparum T. cruzi
<30% 30–50% >50% <30% 30–50% >50%
100 10 (12.3) * 10 (12.3) 61 (75.3) 28 (33.3) 8 (9.8) 45 (56.8)
10 1 (1.2) 0 (0) 80 (98.8) 2 (2.4) 2 (2.4) 77 (95.0)
1 0 (0) 0 (0) 81 (100) 0 (0) 0 (0) 81 (100)
*: percentage of compounds out of the 81 screened in total is shown in parentheses.
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the anti-T. cruzi assays, the reference drug BNZ was included as a control of drug growth 
inhibition; it showed an average IC50 value of 1.72 (0.13) µM, which correlates with that of 
previous reports [31,32]. In the case of P. falciparum, fixed concentrations of chloroquine 
were used as a control of drug growth inhibition in different assays. 
The IC50 values of the 10 compounds tested against P. falciparum ranged from 18.3 to 
110.1 µM (Table 2). Compounds 6g, 33, 60, and 76 showed the highest activity, with IC50 
values around 20 µM (Table 2; Figure 3). It is of interest to note that those compounds 
Figure 2. Parasite growth at three concentrations of representative compounds from different
structural groups. Filled bars represent P. falciparum growth, whereas dark grey bars represent
T. cruzi growth.
2.2. Dose–Response Growth Inhibition Assay
A total of 10 and 28 compounds were selected t progress to dose–respons assays
against P. f lciparum and T. cruzi, respectively, based o the criteria of keeping the growth
of the parasites below 30% at 100 µM. The comp unds’ potency (IC50) was determined
following a 1:2 dilution pattern to conform to dose–response curves. In every round of
the anti-T. cruzi assays, the reference drug BNZ was included as a control of drug growth
inhibition; it showed an average IC50 value of 1.72 (0.13) µM, which correlates with that of
previous reports [31,32]. In the case of P. falciparum, fixed concentrations of chloroquine
were used as a control of drug growth inhibition in different assays.
The IC50 values of the 10 compounds tested against P. falciparum ranged from 18.3 to
110.1 µM (Table 2). Compounds 6g, 33, 60, and 76 showed the highest activity, with IC50
values around 20 µM (Table 2; Figure 3). It is of interest to note that those compounds were
from structurally diverse subgroups (groups C, D1, D5, and D6). Moreover, a wide range
of IC50 values was observed between subgroups (Table 2).
Pharmaceuticals 2021, 14, 638 5 of 23
Table 2. IC50 (µM), TC50 (µM), and SI values of active compounds against P. falciparum and T. cruzi.
P. falciparum T. cruzi Vero Cells HepG2 Cells
Compound Subgroup IC50 IC50 a IC50 b TC50 * SI c SI a SI b TC50 *
BNZ - NT 1.72 1.82 209.5 - 121.80 115.11 255.3
29 C1 NT 4.86 157.3 >1000 - >205.76 >6.36 >1000
6D C2 18.9 5.56 3.78 >150 >7.94 >26.98 >39.68 >200
6g C2 19.08 3.97 19.64 >150 >7.86 >37.78 >7.63 >300
25 D1 81.54 NT NT >6000 >73.58 - - NA
32 D1 69.66 NT NT >1000 >14.36 - - NA
33 D1 19.19 NT NT >300 >15.63 - - NA
34 D1 NT 4.12 4.24 >6000 - >1456.31 >1415.10 NA
59 D5 110.1 NT NT >300 >2.73 - - NT
60 D5 23.3 NT NT >300 >12.87 - - NA
70 D6 NT 13.72 29.08 >50 - >3.64 >1.72 NT
76 D6 18.27 NT NT >500 >27.37 - - NA
84 D6 28.01 NT NT >70 >2.50 - - NT
88 D7 65.35 12.72 35.43 >180 >2.75 >14.15 >5.08 NA
94 D7 NT 0.92 75.11 >60 - >63.16 >0.79 NA
93 E3 NT 1.42 218.2 >2000 - >1408.45 >9.17 NA
a: anti-T. cruzi assay; b: antiamastigote assay; c: anti-P. falciparum assay. *: Values are expressed as the minimum value of the 95% CI, except
for those of BNZ. NT: not tested; NA: not adjusted.
Similarly, IC50 values derived from the anti-T. cruzi assays ranged from 0.94 to
109.90 µM (Table S2). We determined an IC50 cutoff threshold of 10-fold that of the
BNZ IC50 value, in order to progress only those compounds with high activity against the
parasite. Consequently, eight compounds were identified; among those, there were none
from groups A or B, while compounds 94, 93, and 6g—from subgroups D7, E3, and C2,
respectively—exhibited the highest activity, with IC50 values of 0.92 (0.15), 1.42 (0.19) and
3.97 (0.32) µM, respectively (Table 2; Figure 4).
2.3. Identification of Compounds with Specific Antiparasitic Activity
In order to discard those compounds that did not show specific activity against T. cruzi,
we performed a secondary Vero cell toxicity assay [31]; we also included in this assay those
compounds that were active against P. falciparum, in order to assess their toxicity against a
mammalian cell line.
We included the reference drug BNZ, which reached an average TC50 value of 209.5
(15.0) µM, similarly to what had been reported before [31]. At the concentration range
evaluated, which was determined by the maximum percentage of DMSO permitted by
the assay, all compounds had low toxicity to Vero cells. This resulted in flattened curves
that did not allow us to accurately calculate the TC50 values. For this reason, we report
the minimum value of the 95% CI, according to which compounds 25 and 34 showed the
lowest toxicity to Vero cells, followed by compounds 93, 29 and 32 (Table 2). Interestingly,
three of them belonged to subgroup D1.
Regarding the specificity of the activity of the compounds against P. falciparum and
T. cruzi, most of them yielded high selectivity index (SI) windows, with values depicting
their cytotoxicity contribution as being insignificant. Generally, SI values > 10 are suitable
for progression in the screening cascade [33]. Five of the ten compounds active against
P. falciparum displayed SI values > 10 (Table 2). Among those, compound 25 reached the
highest SI index, with a value > 73.6 (Table 2). Compounds 6D, 6g, 59, 84, and 88—with
SI values < 10—were discarded from further progression. On the other hand, seven of the
eight compounds active against T. cruzi had SI values > 10. Indeed, compounds 29, 34,
and 93 showed higher SI values than that of the standard drug BNZ itself (Table 2). Only
compound 70 had an SI < 10 against T. cruzi (Table 2).
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2.4. HepG2 Cell Toxicity Assay
We also assessed the toxicity of the active compounds against both parasites in an assay
based on human HepG2 cells, which are a commonly used cell-based model to anticipate
potential liver toxicity [34,35]. The TC50 of the reference drug BNZ was 255.3 (10.8) µM,
which was similar to that previously reported [31]. As mentioned above, we reported the
HepG2 toxicity as the minimum value of the 95% CI since they all had a low toxicity. All
compounds tested against HepG2 cells showed lower toxicity to this cell line than to Vero
cells (Figure 5; Table 2), and only compound 6D turned out to be more toxic than BNZ to
HepG2 cells (Table 2). Representative dose–response curves of some of the compounds
tested against Vero and HepG2 cells are shown in Figure 5.
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2.5. Antiamastig te Growth Inhibition Assay
We next teste those compounds that showed specific activity against T. cruzi with an
assay carried out on intrac llular amastigot s, wh h are considered to be the main targe s
for an pr pective drug against chronic T. cruzi infections. The reference drug BNZ was
included in each antiamastigote assay, and reported an average IC50 value of 1.82 (0.08) µM.
Overall, the ompounds’ specific antiamastigote activity was lower than that observed in
the antiparasitic assa previously escribed, excluding that of compound 6D.
In fact, only compounds 6D and 34 complied with th IC50 cutof threshold of 10-fold
that of BNZ, reaching IC50 values f 3.78 (0.31) µM and 4.24 (0.29) µM, respectively (Table 2,
Figure 6). B th c mpounds yielded SI values > 10 against Vero cells, with that of com und
34 being outst nding (SI > 1415.10; Table 2).
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2.5. Antiamastigote Growth Inhibition Assay 
We next tested those compounds that showed specific activity against T. cruzi with 
an assay carried out on intracellular amastigotes, which are considered to be the main 
targets for any prospective drug against chronic T. cruzi infections. The reference drug 
BNZ was included in each antiamastigote assay, and reported an average IC50 value of 
1.82 (0.08) µM. Overall, the compounds’ specific antiamastigote activity was lower than 
that observed in the antiparasitic assay previously described, excluding that of com-
pound 6D. 
Table 2. IC50 (µM), TC50 (µM), and SI values of active compounds against P. falciparum and T. cruzi. 
  P. falciparum T. cruzi Vero Cells HepG2 Cells 
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squares. Graphs represent mean values and SD results of at least three independent replicas.
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2.6. Co putational nalysis
Biological assays led to the identification of two hit compounds (2.5% hit rate) against
each parasite. In order to identify potential targets of those compounds, we performed an in
silico docking study with enzymes from the purine salvage pathways of both parasites. The
lowest free binding energy (i.e., best docking score) indicates the highest ligand/protein
affinity. The docking study with the compounds was conducted in comparison with en-
zymes’ natural ligands, as these compete for the active binding site. In general, compounds
showed lower binding energy values than natural ligands (Tables 3 and 4). Compounds 33
and 76 reported the lowest binding energy values when docked against the Pf HGXPRT
enzyme (Table 3). Indeed, the energy difference between both compounds and natural
ligands was the highest among docked enzymes (Table 3). Both compounds also reported
considerably higher energy differences when docked against P. falciparum adenosine deam-
inase (Pf ADA). Even though P. falciparum adenylosuccinate synthetase (Pf ADSS) reported
low binding energy values for compounds, it also did so for its natural ligand—inositol
monophosphate (IMP; ∆G = −9.49 (0.03) Kcal/mol). Regarding hit compounds against
T. cruzi, 6D reported the lowest binding energy values with T. cruzi adenosine kinase (TcAk;
∆G =−9.20 (0.00) Kcal/mol) and T. cruzi inosine-guanosine nucleoside hydrolase (TcIGNH;
∆G =−9.10 (0.02) Kcal/mol), while 76 did so with T. cruzi inosine-adenosine-guanosine nu-
cleoside hydrolase (TcIAGNH; ∆G = −10.09 (0.17) Kcal/mol) and T. cruzi adenylosuccinate
lyase (TcADSL; ∆G = −10.08 (0.32) Kcal/mol). However, contrary to P. falciparum docking
results, the difference in binding energy values between the compounds and the natural
ligands of those enzymes was not the highest (Table 4). The highest energy difference value
of both compounds was shown for TcHGPRT (Table 4).
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Table 3. Free binding energies of molecular docking between natural ligands and hit compounds with enzymes from the




















−9.91 (0.08) −10.30 (0.02)
−3.11 −3.50
Hypoxanthine −5.73 (0.26) −4.18 −4.58
Guanine −6.65 (0.05) −3.26 −3.65
PfADA (XP_001347573.1) Adenosine −7.10 (0.00) −9.05 (0.05) −9.22 (0.09) −2.12 −1.95
PfGMPS (XP_001347408.1) XMP −6.63 (0.12) −8.19 (0.19) −8.51 (0.06) −1.56 −1.88
PfPNP (XP_001351690.1) Inosine −7.13 (0.04) −8.51 (0.14) −8.83 (0.46) −1.38 −1.71
PfADSL (XP_001349577.1) SAICAR −8.10 (0.13) −9.27 (0.11) −9.15 (0.06) −1.17 −1.05Adenylosuccinate −8.41 (0.12) −0.86 −0.74
PfADSS (XP_001350257.1) IMP −9.49 (0.03) −9.62 (1.02) −8.51 (0.31) −0.13 0.98
Table 4. Free binding energies of molecular docking between natural ligands and hit compounds with enzymes from the

















TcHGPRT (XP_813396.1) Hypoxanthine −4.80 0.00) −7.92 (0.04) −8.64 (0.13) −3.12 −3.84Guanine −5.49 (0.03) −2.43 −3.15
TcAPRT (XP_818435.1) Adenine −5.40 (0.02) −7.64 (0.34) −8.37 (0.36) −2.23 −2.97
TcAK (XP_820251.1) Adenosine −7.24 (0.10) −9.20 (0.00) −9.72 (0.09) −1.96 −2.48
TcIGNH (XP_818171.1) Inosine −7.62 (0.09) −9.10 (0.02) −9.25 (0.11) −1.48 −1.63Guanosine −8.22 (0.20) −0.88 −1.03
TcIMPDH (XP_805772.1) IMP −7.99 (0.03) −8.19 (0.04) −9.12 (0.24) −0.20 −1.13
TcIAGNH (XP_804829.1)
Inosine −9.40 (0.00)
−8.92 (0.13) −10.09 (0.17)
0.48 −0.69
Guanosine −9.33 (0.27) 0.41 −0.76
Adenosine −8.85 (0.05) −0.07 −1.21
TcADSL (XP_811726.1) SAICAR −9.26 (0.08) −8.50 (0.00) −10.08 (0.32) 0.76 −0.82Adenylosuccinate −9.45 (0.06) 0.95 −0.63
Sequence ID references at NCBI are shown for each enzyme. Energy difference value is calculated as the difference between the binding
energy of the compound and that of the natural ligand.
For both parasites, Pf HGXPRT and TcHGPRT docking results were chosen for visual-
ization due to their high energy differences between the binding of compounds and natural
ligands. Such visualization revealed that the compounds bind to the active site occupying
more space of the cavity than the natural ligands of both enzymes (Figures 7A,B and 8A,B).
In both cases, hypoxanthine is located in a hydrophobic area of the binding pocket.
Interestingly, an aromatic group of each compound is located in the binding site of hy-
poxanthine, while the rest of the molecule extends to the pyrophosphate, ribose, and
5’-phosphate binding sites (Figures 7 and 8). In all cases, electronegative atoms of the
purine base tend to locate in a more electronegative and hydrophilic area of the binding
site (Figures 7A,B and 8A,B).
In Pf HGXPRT, compound 33 is found entirely inside the cavity, while in compound
76 the substitution at C6 remains out (Figure 7A,B). Hypoxanthine forms four hydrophobic
interactions and five H bonds with aspartic (D) 148, lysine (K) 176, and valine (V) 198.
Residues of tyrosine (T) 116 and phenylalanine (F) 197 are involved in a pi–pi stacking
interaction (Figure 7C). Compound 33 was found to have eight hydrophobic interactions,
sharing three of them with hypoxanthine. In compound 33, two nitrogen atoms from the
triazole group form two hydrogen bonds with Y116, and the oxygen at position C6 interacts
by forming two hydrogen bonds with threonine (T) 152 and serine (S) 115 (Figure 7C).
Hydrophobic interactions in compound 76 were observed with isoleucine (I) 146, F197,
asparagine (N) 206, and leucine (L) 207. In compound 76, the nitrogen from the 1-thiazol-
4-ylmethyl group and the N1 from the purine ring interact with K114 via two hydrogen
bonds (Figure 7C). Interestingly, there is no hydrogen bond shared between hypoxanthine
and the compounds, whereas hydrophobic interactions that involve I146 and F197 are
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present in all three bindings, and the interaction with Y116 in the binding of hypoxanthine
and compound 33.
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In TcHGPRT, the 6-benz y and 8-phenyl substitution of compounds 6D and 34
occupied the location of hypoxanthine. Hypoxa thine forms two hydrophobic interactions
with L170 and I113, and three hydrogen bonds with D115, K143, and V165 (Figure 8C).
Compound 6D only forms one hydrogen bond with arginine (R) 177, but was found to
have seven hydrophobic interactions—those with I113, L170, and F164 being shared with
hypoxanthine (Figure 8C). On the other hand, compound 34 forms hydrophobic interac-
tions with V92, I113, and F164, and hydrogen bonds with residues T119, L118, and T116
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(Figure 8C). Similarly to Pf HGXPRT bindings, there is no hydrogen bond shared between
hypoxanthine and the compounds, while the hydrophobic interaction with isoleucine I113
and the pi–pi stacking interaction with F164 are present in all three bindings.
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3. Discussion
Targeted design of new drugs is an interesting strategy to specifically inhibit key
enzymes diverging between the parasite pathogens and their hosts. Most of the protozoan
parasites, including P. falciparum and T. cruzi, depend on the purine salvage pathway.
Thus, targeting the purine metabolism could be a valuable approach for the design of new
drugs against these infectious diseases. In this study, we screened a synthetic collection
of 81 structurally related purines and pyrimidines in a target-agnostic manner, in order
to identify those with the highest specific antiparasitic activity in vitro. Notably, from a
structural standpoint, compounds within this collection can be classified in five distinct
chemical groups [36].
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Among those compounds that were specifically active against both parasites, we
found three belonging to chemical group C, characterized by the presence of a benzoxy
group at position C6 of the purine ring (Figure 1). Compound 29, from subgroup C1, was
the fifth most potent compound (IC50 = 4.86 (0.65) µM) against T. cruzi; this compound
features a methylpiperazine group at N9 and no substitution at C8 (Figure 1). Compounds
6D and 6g, from subgroup C2, showed activity against both parasites, but reported an
SI value < 10 against P. falciparum. Compound 6g was the third most potent compound
(IC50 = 3.97 (0.32) µM) against T. cruzi, showing a specific antiparasitic activity in com-
parison to Vero and HepG2 cells; in this compound, the three positions of the purine
ring are substituted with an aromatic group (Figure 1). Compound 6D, with a tert-butyl
instead of an aromatic substitute group at N9, showed lower activity against T. cruzi
(IC50 = 5.56 (0.33) µM, Table 2). Nevertheless, it was the only compound from this group
with specific antiamastigote activity (IC50 = 3.78 (0.31) µM; Table 2). 6-Benzoxy purines
with voluminous groups at N9 were more active against T. cruzi than those with small
substituents in the anti-T. cruzi assay, but did not show activity against amastigote forms.
In addition, the presence of a phenyl group at C8 seems to play an important role. In
this regard, Hulpia et al. reported promising in vitro and in vivo activities of certain C7
phenyl-substituted analogs against T. cruzi [24]. The use of aromatic groups, such as the
ones presented in those compounds, is recurrent in the design of purine inhibitors [23,37].
For instance, Harmse et al. demonstrated that the presence of a voluminous aromatic
ring in the purine structure had antimalarial activity [37]. In addition, Singh et al. re-
ported IC50 values < 5 µM for nucleoside homologs stabilized with aromatic rings against
P. falciparum [23]. Moreover, our own works demonstrate that a compound synthesized
by similar synthetic strategies and featuring a 6-benzoxy group at C6 position has high
activity against T. brucei (IC50 = 1 (0.1) µM) [28].
Compounds belonging to group D are characterized by the presence of an N-substituted
triazolylmethoxy group at position C6 of the purine ring (Figure 1). All compounds that
were specifically active against P. falciparum belonged to this group, highlighting the rel-
evance of this chemical substituent against P. falciparum. The closely related structure of
these compounds suggests a common target in P. falciparum. Moreover, the activity of
triazole-based compounds has already been reported against this parasite [38]. For instance,
triazolopyrimidine hybrids were identified as being potent in vitro and in vivo inhibitors
of P. falciparum growth [38]. The role of the triazole group against T. cruzi is not so clear,
since just four out of seven compounds present this substituent. However, triazole-based
drugs have also been described as possessing high in vitro activity against T. cruzi [39,40].
Taking a deeper insight into chemical group D, we found that active compounds
against both parasites belonged to subgroups D1, D5, D6, and D7. Active compounds
against P. falciparum from subgroup D1 principally differ in the position of the methoxy
group attached to the phenyl ring that substitutes the triazole (Figure 1). The anti-
P. falciparum potency of compounds 25, 32, and 33 ranged from 19.2 to 81.5 µM, and
increased in relation to bearing a methoxy group in the positions para < meta < ortho. Interest-
ingly, the toxicity of those compounds to Vero cells also increased following the same chem-
ical substitution pattern. From this subgroup, only compound 34 showed activity against
T. cruzi (IC50 = 4.12 (0.41) µM), yielding the highest SI rate against Vero cells (SI > 1456.31)
(Table 2); this activity was kept against amastigote forms (IC50 = 4.24 (0.29) µM, SI > 1415.10)
(Table 2). Compound 34 shares a phenyl group at C8 with compound 6D, which is the only
other compound displaying specific antiamastigote activity; moreover, both compounds
have a small substituent at N9.
In subgroup D5, only compound 60 showed specific activity against P. falciparum, while
compound 59 was discarded due to its low selectivity with respect to Vero cells. Although
the toxicity of both compounds to Vero cells was similar, the IC50 value of compound 60
was around five times lower than that of compound 59 (Table 2); structurally speaking, the
main difference between these compounds is that compound 60 carries a 2-methoxyphenyl
group at position N1 of the triazole, while 59 displays a 3-methoxyphenyl group (Figure 1).
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Thus, as occurs with chemical subgroup D1, a similar trend between structure and activity
is observed. Interestingly, compounds belonging to subgroup D5 are the pyrimidine Schiff
base analogs of those from subgroup D1. There were no statistically significant differences
in the effects on P. falciparum growth between the active compounds and the correspondent
pyrimidine analogs. For example, compound 33 had an IC50 = 19.19 (1.1) µM, while its
pyrimidine Schiff base analog 60 showed an IC50 = 23.3 (1.06) µM (Table 2). It is of interest
to note that almost all compounds from subgroup D5 reported activity against T. cruzi,
even though their IC50 values were > 10-fold higher than the BNZ IC50 value and, thus,
were not progressed to toxicity assays.
Compound 76, from subgroup D6, was the most potent of the collection against
P. falciparum (IC50 = 18.27 (1.07) µM; Table 2). Compound 84, with an IC50 value 1.5 times
higher against this parasite, had an SI < 10 against Vero cells, and was thus discarded.
While both compounds possess a thiazole-4-yl-methyl group connected at the triazole
moiety at C6 of the purine ring, and a phenyl group at C8, they differ in position N9, where
76 features a piperidine ring and 84 a methylpiperazine (Figure 1). That increased basic
character of 84 may be involved in the toxicity increase against Vero cells. The high activity
of compound 76 may be related to the voluminous substituent at position N9, which could
fit in the ribose pocket of the target enzyme(s). From this subgroup, only compound 70
displayed activity against T. cruzi, although it was toxic to Vero cells, and discarded for its
SI < 10 (Table 2).
Within subgroup D7, we found that compound 88 presented activity against both
parasites; it has a similar structure to that of compound 32, but no substitution at C8,
and a tert-butyl at position N9, yet it showed an IC50 value close to that observed for 32
against P. falciparum. Nevertheless, it had an SI < 10 against this parasite, and was thus
discarded. On the other hand, this same compound showed an IC50 value of 12.72 µM
against T. cruzi (Table 2). Compound 94 was the most potent of the collection in the
anti-T. cruzi assay (IC50 = 0.92 (0.15) µM; Table 2), and also belonged to the same chemical
group; it shared with 88 the 1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-ylmethoxy group
at C6 and no substitution at C8; however, compound 94 presents a methylpiperazine
group instead of a tert-butyl at position N9, which considerably increases its potency
against T. cruzi (Figure 1). Interestingly, the methylpiperazine group decreased the activity
of 94 against amastigote forms, yielding an IC50 value of 75.11 (6.4) µM (Table 2); this
structure–activity relationship (SAR) was previously observed with compounds from
group C. In agreement with previous results obtained with compounds 76 and 84, the basic
methylpiperazine group at N9 of compound 94 seemed to increase the toxicity against Vero
cells (TC50 > 60 µM) compared to non-basic substituents, such as the tert-butyl substitution
present in compound 88 (TC50 > 180 µM) (Table 2).
Finally, compound 93, from chemical group E, was the second most potent compound
of the collection in the anti-T. cruzi assay (IC50 = 1.42 (0.19) µM; Table 2). Similarly to
compound 94, when assessed against intracellular amastigotes, its activity considerably
decreased (IC50 = 218.2 (69.1) µM; Table 2); it shared with compound 94 a methylpiperazine
at N9 and no substitution at position C8, despite their being from different chemical groups
(Figure 1). The 3-methoxyphenyl triazolyl methoxy group at position C6 of compound 94,
as opposed to the propargyloxy moiety present in compound 93, seemed to increase
its anti-T. cruzi activity. Interestingly, compound 29, from subgroup C2, also shared a
methylpiperazine at N9 and no substitution at C8 (Figure 1). Nevertheless, the presence
of a benzoxy group at C6 could explain its lower anti-T. cruzi activity and selectivity
(IC50 = 4.86 (0.65) µM, SI >205.8) in comparison to compound 93 (IC50 = 1.42 (0.19) µM,
SI > 1408.45) (Table 2). It is also interesting to note that the toxicity to Vero cells of those
three compounds increased as the substituent of C6 became more voluminous, although all
reached high SI values (Table 2). Similarly, the potency against amastigote forms of those
three compounds also increased following this substitution pattern (Table 2).
In vitro assays led to the identification of compounds 33 and 76 as hit compounds
against P. falciparum, and compounds 6D and 34 against T. cruzi. Since purine derivatives
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aim to target parasites´ purine salvage pathways, we performed an in silico docking study
with available 3D structures or computationally generated models of the enzymes involved
in these pathways. As natural ligands would be competing against those compounds
for binding to the active site, we considered the differences in binding energy between
compounds and natural ligands as the main parameter by which to elucidate potential
targets. Thus, compounds 33 and 76 reported the highest differences in energy when
docked with Pf HGXPRT (Table 3). Moreover, both compounds were bound with the highest
affinity to that among all P. falciparum enzymes. Similar results were obtained for Pf ADA,
suggesting that both enzymes could be potential targets. Regarding compounds 6D and 34,
the highest energy difference was also shown against TcHGPRT (Table 4). Similarly, TcAPRT
reported considerable enough energy differences for both compounds to be considered a
potential target (Table 4).
Visualization of Pf HGXPRT and TcHGRT docking results revealed that compounds
cover a more extensive space of the active site than the natural ligand, hypoxanthine
(Figures 7 and 8). Hypoxanthine re-docking with Pf HGXPRT correlates with the co-
crystalized complex, and its binding with TcHGPRT with previous reports [41]. In all
cases, an aromatic group of each of the compounds prioritized was observed occupying
the hydrophobic binding pocket of the hypoxanthine (Figures 7A and 8A). Hydrophobic
interactions are the main driving force in drug–receptor interactions, and the most frequent
in high-efficiency ligands [42]. In general, the compounds showed more hydrophobic
interactions than hypoxanthine. In Pf HGXPRT, interaction with I146 and a pi–pi stacking
interaction with F197 were present in all bindings, while that involving Y116 was observed
with compound 33 and hypoxanthine (Figure 7C). In TcHGPRT, compounds 6D and
34 shared with hypoxanthine a hydrophobic interaction with I113 and a pi–pi stacking
interaction with F164 (Figure 8C). Hydrogen bonds are the second most common type
of interaction between proteins and ligands [42]. Compounds formed fewer hydrogen
bonds with HGPRT enzymes than did natural ligands, with the exception of compound
34. None of the compounds shared hydrogen bonds with hypoxanthine. The frequency of
hydrogen bonds was reduced from 59% to 34% of that of hydrophobic contacts in efficient
ligands [42], which correlates with the types of interactions that the compounds formed,
and with their high binding affinities. However, our docking study did not consider water
molecules, or the flexibility of the residues of the active site. Hit compounds lack polar
hydrogens, but present a high quantity of heteroatoms that might form water-mediated
hydrogen bonds with other residues.
All of the compounds showed a similar binding mode between them, and seemed to
share fundamental hydrophobic interactions. An aromatic group of each compound located
to the hypoxanthine binding site, while the rest of the molecule occupied the pyrophosphate,
ribose, and 5′-phosphate binding sites of either Pf HGXPRT or TcHGPRT. Compounds 33
and 76 showed a similar binding mode to those of previously described immucillin 5′-
phosphates and acyclic nucleoside phosphonates [25,43,44]. Immucillin 5′-phosphates
are transition state analogs of Pf HGXPRT, with Ki values between 1 and 4 nM [43], and
several immucillins have undergone preclinical evaluation in malaria animal models [45,46].
Compounds within acyclic nucleoside phosphonates replace the labile phosphate group of
immucillins with a phosphonate, avoiding the activity of phosphomonoesterases.
Regarding TcHGPRT, compounds 6D and 34 seem to bind similarly to two compounds
of the collection described by Freyman et al. [18]. All of the compounds bind within the
central region of the binding site, and share interactions with F164 and I113 [18]. Other
studies targeting TcHGPRT identified purine analogs with electronegative atoms bound
to C6 of the purine ring [21], which is also the case with our collection. In compound 34,
electronegative atoms of the substitution at C6 of the purine ring resemble interactions
of the 5′-phosphate group with loop III (residues 111 to 120) [18]. The N9 of the purine
base is a key position in the HGPRT’s catalyzed reaction, since it is the site where the
ribose of phosphoribosyl pyrophosphate (PRPP) is covalently linked to the purine base
during nucleotide formation [47]. Consequently, the removal of this free amino group
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from the purine scaffold by the formation of N-substituted analogs would prevent the
enzymatic incorporation of PRPP to the purine ring. This structural feature is present
in our compound library, with the best candidates bearing, at position N9, a piperidin-
1-yl in compound 76, a tert-butyl in compound 6D, and a N,N-dimethylamino group in
compounds 33 and 34 (Figure 9). This structural feature might suggest that, if HGPRT is
the target of the compounds, those would be acting as true inhibitors and not as alternate
substrates [21]. In any case, confirmation of HGPRT as a potential target should be carried
out via enzymatic assays and/or compound crystallization in complex with the enzyme.
Such assays may also be performed with the Pf ADA and TcAPRT enzymes, considering
the binding energies reported in the in silico docking study.
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4. Mat rials and Methods
4.1. Chemical Collection
The compound library is comprised of 81 purine derivatives that belong to 5 different
families (A–E) (Table 5). All of the compounds were synthesized nd characterized by
1H-NMR, 13C-NMR, and HRMS. The synthesis and structural characterization data of
purines from library groups A, D, and E were previously reported [29,48,49]. Structural
characterization data (1H-NMR, 13C-NM , and HRMS) from purine derivatives belonging
to families B and C can be found in the Supplementary Materials. Compounds were first
screened at 1, 10, and 100 µM, and those progressed were assayed in a dose–response
manner at starting concentrations of 100, 200, or 400 µM. The final DMSO percentage per
well was in all cases below 0.5%.
4.2. Host Cell Cultures
Human erythrocytes were purified from B+ Rh+ blood samples and maintained at
4 ◦C in incomplete RPMI medium. Vero (green monkey kidney epithelial cells), LLC-
MK2 (Rhesus monkey kidney epithelial cells), and HepG2 (human liver epithelial cells)
cultures were cultivated in DMEM supplemented with 1% penicillin–streptomycin (PS)
and 10% heat-inactivated fetal bovine serum (FBS) at 37 ◦C, 5% CO2, and >95% humidity,
as described in [31]. HepG2 cells were also supplemented with 10% non-essential amino
acids. Vero and MK2 cells were passaged twice per week at 1:12 ratios, while HepG2 cells
were passaged at a 1:8 ratio.
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Table 5. Classification of the compounds within the chemical collection evaluated in this study.
Group Scaffold Sub-Group Chemical Name Number ofCompounds
A 6-Alkoxy-purines
A1 6-Ethoxy-8-(H or methyl)-9-substituted-9H-purines 4
A2 8-(H or Methyl)-6-isopropoxy-9-isopropyl-9H-purines 2
B 6-Tert-butyl amino purines - 9-tert-Butyl-6-(tert-butylamino)-8-substituted-9H-purines 3
C 6-Benzoxy-purines
C1 6-Benzoxy-9-substituted-9H-purines 4














D6 9-(Alkyl or Dialkylamino)-8-phenyl-6-{[1-(thiazol-4-ylmethyl)-1H-1,2,3-triazol-4-yl]methoxy}-9H-purines 5









E2 9-(Alkyl orDialkylamino)-8-phenyl-6-propargyloxy-9H-purines 4
E3 9-(Alkyl or Dialkylamino)-6-propargyloxy-9H-purines 4
4.3. Culture of P. falciparum and T. cruzi Parasites
P. falciparum 3D7 parasites were cultured with human erythrocytes in RPMI medium
supplemented with 25 mM HEPES, 100 µM hypoxanthine, 25 mM bicarbonate, 5.5 mM
glucose, 110 µM gentamicin, and 0.5 % AlbuMAX II. Apicomplexan parasite cultures were
maintained at 3% hematocrit under an atmosphere of 37 ◦C in 93% N2, 5% CO2, and 2%
O2, following standard methods [50]. Synchronized cultures were obtained via 5% sorbitol
lysis [51].
T. cruzi parasites from the Tulahuen strain (discrete typing unit (DTU) VI) express-
ing β-galactosidase were maintained in culture by the infection of LLC-MK2 cells in
DMEM supplemented with 2% FBS and 1% penicillin–streptomycin–glutamine (PSG),
as described in [52]. When free-swimming trypomastigotes were released to the culture
medium, they were centrifuged for 7 min at 2500 rpm and allowed to swim out of the
pellet. Trypomastigotes were used to maintain the parasite cycle, or for the performance of
the antiparasitic assays.
4.4. P. falciparum Primary Screening and Growth Inhibition Assay
P. falciparum growth was primarily analyzed under 3 different concentrations (100,
10, and 1 mM) of the 81 compounds. Conditions were tested in triplicate for every con-
centration, and the test was repeated when the standard deviation was above 10% for any
concentration. Z-values varied between 0.83 and 0.98 in the different plates analyzed [53].
Selected compounds (12.3% potential hit rate) were further analyzed via standard growth
inhibition assays, carried out as previously described in [54]. Briefly, parasitemia was ad-
justed to 1–1.3%, with >90% rings after sorbitol synchronization. Two hundred microliters
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of parasite culture were plated in 96-well microplates and incubated for 48 h at 37 ◦C in the
presence of decreasing concentrations of the tested compounds, in triplicate. Parasitemia
was determined by fluorescence-assisted cell sorting (FACS). Non-infected RBCs and sam-
ples containing parasitized RBCs (including controls with DMSO as carrier solvent) were
diluted in PBS to a final concentration of ~1–10 × 106 cells/mL. The cell suspension was
stained with SYTO 11 (0.5 mM stock in DMSO, Thermo Fisher Scientific, Waltham, MA,
USA), to a final concentration of 0.5 µM. Samples were analyzed in a Becton Dickinson
FACSCalibur. Sample excitation was carried out using a 488-nm, air-cooled argon-ion
laser at a power of 15 mW, using forward and side scatter to gate the RBC population,
and SYTO 11 green fluorescence (530 nm, FITC filter) was collected in a logarithmic scale.
The single-cell population was selected on a forward–side scattergram, and the green
fluorescence from this population was analyzed. Parasitemia was expressed as the number
of parasitized cells per 100 erythrocytes.
4.5. T. cruzi Primary Screening and Growth Inhibition Assay
T. cruzi growth was primarily analyzed under three different concentrations (100, 10,
and 1 mM) of the 81 compounds. Conditions were tested in triplicate for every concentra-
tion. Z-values varied between 0.81 and 0.92 in the different plates analyzed [53]. Selected
compounds (34.6% potential hit rate) were further analyzed via standard growth inhibi-
tion assays [31]. The Z-values of dose–response assays correlated with those previously
reported [31]. For both assays, Vero cells and trypomastigotes from the Tulahuen T. cruzi
strain expressing β-galactosidase [52] were harvested, centrifuged, and resuspended in
DMEM without phenol red supplemented with 1% PSG, 2% FBS, 1 mM sodium pyruvate,
and 25 mM HEPES. Vero cells and trypomastigotes were counted, diluted at a concentration
of 1 × 106 cells/mL each, and mixed 1:1 (v/v). Then, 100 µL of that mixture was added
per well to the plates already containing the compounds. Each well contained 50,000 host
cells and 50,000 parasites, i.e., multiplicity of infection (MOI) = 1. BNZ was used as control
of maximal drug growth inhibition in each round, whereas each plate contained its own
negative control (maximum parasite growth; Vero cells plus parasites without drugs) and
positive control (minimum parasite growth; trypomastigote forms alone marking an enzy-
matic zero time or baseline galactosidase activity) [31]. After four days at 37 ◦C, 50 µL of a
PBS solution containing 0.25% NP40 and 500 µM chlorophenol red-β-D-galactopyranoside
(CPRG) substrate were added per well [32]. Plates were incubated at 37 ◦C for 4 h, and
their absorbance read out at 590 nm using an Epoch Gene5 spectrophotometer.
4.6. Vero and HepG2 Toxicity Assays
Vero and HepG2 cells were detached, centrifuged, and resuspended in DMEM without
phenol red. Cell viability was checked upon cell counting with trypan blue staining. Then,
Vero and HepG2 cells were diluted at a concentration of 5 × 105 and 3.2 × 105 cells per mL,
respectively, before adding 100 µL per well to the 96-well plate. Each run contained its own
negative (untreated cells) and positive (medium alone) controls [31]. Plates were incubated
at 37 ◦C for 4 days in the case of Vero, or 2 in the case of HepG2 cells. Assay readout
was made by adding 50 µL per well of a PBS solution containing 10% alamarBlue reagent
(Thermo Fisher Scientific); then, plates were incubated for another 6 h at 37 ◦C, before
recording the fluorescence intensity with a Tecan Infinite M Nano+ reader (excitation:
530 nm, emission: 590 nm) [31].
4.7. Antiamastigote Specific Assay
Vero cells were seeded in T-175 flasks (5 × 106 cells per flask) in DMEM supplemented
with 1% penicillin–streptomycin and 10% FBS, and cultured for 24 h. Then, cells were
washed once with PBS, and free-swimming trypomastigotes (1 × 107 trypomastigotes per
flask; MOI = 1) in assay medium were added and allowed 18 h to infect [55]. After that,
infected cell monolayers were washed with PBS and detached. Cells were counted and
diluted to a concentration of 5 × 105 cells per mL, before adding 100 µL per well to test
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plates already containing the drugs dispensed as described above [55]. In all cases, we
included BNZ as control drug, and each plate contained its own negative (Vero cells and
parasites) and positive (Vero cells) controls [55].
4.8. Computational Analysis
A computational approach was followed to elucidate the mechanism behind the ac-
tion of these compounds. A curated search of enzymes involved in the purine salvage
pathway was performed in the two specialized databases of our organisms of interest
from the Eukaryotic Pathogen, Vector, and Host Informatics Resource (VEuPathDB) [56]:
PlasmoDB [57] for P. falciparum, and TriTrypDB [58] for T. cruzi. For P. falciparum, proteins
selected consisted of ADA, ADSL, ADSS, GMP synthase (GMPS), HGXPRT, inosine-5′-
monophosphate dehydrogenase (IMPDH), PNP, and nucleoside transporters 1 to 4 (NT1–
NT4). For T. cruzi, the enzymes selected consisted of ADA, ADSL, ADSS, AK, adenine
phosphoribosyltransferase (APRT), guanine deaminase (GD), HGPRT, IAGNH, IG-NH,
inosine-5′-monophosphate dehydrogenase (IMPDH), and methylthioadenosine phospho-
rylase (MTAP). Two transporters were also selected: nucleoside transporter 1 (NT1) and
nucleobase transporter 2 (NB2). Since the Tulahuen strain is not well annotated, all entries
were obtained from the CL Brener Esmeraldo-like strain. Entries were obtained for the
P. falciparum 3D7 strain. All of the selected proteins are summarized in Table S3.
Selected proteins were queried for their NCBI [59] RefSeq entries, and these were
blasted with BLASTP [60] against the human (taxid: 9606) non-redundant (nr) protein
database, using default scoring parameters and an expect threshold of 20,000. The highest
identity hit for each query, measured as the number of identical positions divided by the
total length of the queried protein, was selected. Each selected protein was also blasted
against the Protein Data Bank (PDB) database [61], using the PAM30 matrix with a word
size of 2, no compositional adjustments, gap existence cost of 9, and extension cost of 1,
with an expect threshold of 20,000. The highest identity hit was selected as described above
(Table S3). Selected PDB hits with an identity above 99% with the curated protein were
directly used for docking simulations. Parasites’ proteins that did not have any PDB hits
with an identity of at least 50% were discarded from further analysis.
PDB entries with an identity between 50% and 99% were submitted to comparative
modelling with the MODELLER [62,63] Python package in order to generate 3D structures
to be used in docking simulations. The methodology for this approach consisted of a
two-step process: first, an alignment of the RefSeq entry with the sequence of the PDB
record, and second, the generation of five 3D models with MODELLER’s AutoModel class
for each protein, using the previous alignment and the atom coordinates from the PDB
record as a template. The best model for each round was selected according to the highest
GA341 [64] and lowest DOPE [65] scores. While the DOPE score can only be used to select
the best structure from a collection of models built by the program for the same protein,
the GA341 score can be used to generally assess the reliability of any given model. All of
the models generated for this work scored 1 for this method—the highest possible value,
and comparable with low-resolution structures [64].
Both high-identity PDB entries and computationally generated models were prepared
for docking simulations. Water molecules, if present, were removed, and Kollman charges
and polar hydrogens were added using AutoDockTools 1.5.6 [66]. Resulting structures
were formatted as PDBQT files. PDB entries with co-crystallized cofactors were processed
with and without them, generating two versions for each entry. 3D structures for the
selected compounds were generated with Avogadro 1.2.0 [13], and their molecular ge-
ometry was optimized until the lowest energy values were obtained. Natural ligands’
3D structures were obtained from PubChem [67] as SDF files, as follows: adenine (Pub-
Chem ID 190), adenosine (PubChem ID 60961), adenylosuccinic acid (PubChem ID440122),
guanine (PubChem ID 135398634), guanosine (PubChem ID 135398635), hypoxanthine
(PubChem ID 135398638), inosine (PubChem ID 135398641), inosine monophosphate (IMP)
(PubChem ID 135398640), SAICAR (PubChem ID 160666), xanthine (PubChem ID 1188),
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and xanthosine monophosphate (XMP) (PubChem ID 73323). PDBQT files of the ligands
were also generated with AutoDockTools, with all the default values accepted.
Docking was performed with AutoDock Vina 1.1.2 [68]. The binding box used was
centered on the active site of each enzyme, using data from the PDB and/or literature
(Table S3); ligands’ binding boxes were constrained to any previously described position, if
possible. Exhaustiveness was set to 12, and energy range to 4. Each round of docking with
AutoDock Vina produced 9 different binding modes, from which the mode with the lowest
binding energy (in Kcal/mol) was selected. This was repeated 100 times for each enzyme’s
natural ligand(s) and compounds, using a different random seed each round; in structures
with cofactors, docking simulations were repeated with and without these present. Means
and standard deviations for the binding energies were calculated with the values from the
selected 100 best binding modes. LigPlot+ v.2.2.4 [69] was used to analyze different types
of protein–ligand interactions with default parameters, and PyMOL 2.4.1 [70] was used to
visualize and image the results. A hydrophobicity surface map was generated for selected
enzymes using the Kyte–Doolittle hydrophobicity scale [71], and the electrostatic potential
map was generated using PyMOL’s APBS Electrostatics plugin [72].
4.9. Data Analysis
Absorbance values derived from the anti-T. cruzi assays and fluorescence values
from the anti-P. falciparum and cell toxicity assays were normalized to the controls [33].
In the primary screening at three fixed doses, the compounds’ inhibitory activity was
expressed as a percentage of the negative control (100% parasitic growth). In dose–response
assays, the compounds’ IC50 and TC50 values were determined with GraphPad Prism 7
software (version 7.00, 2016), using a non-linear regression analysis model defined by the
following equation:




IC50 and TC50 values are respectively provided as means and standard deviations (SD),
or as the minimum value of the 95% confidence interval (CI) of at least three experiments.
5. Conclusions
In this study, we analyzed the antiparasitic activity of a library of 81 purine and
pyrimidine analogs by screening them against P. falciparum and T. cruzi. Around 50% of
these molecules showed some biological activity by inhibiting parasites’ growth, and the
majority of them had low toxicity to Vero and HepG2 cells. The most potent hits against
P. falciparum were purines 33 and 76, with IC50 < 20 µM, both sharing an N-substituted
triazolylmethoxy group at C6, a tertiary amine at N9, and a phenyl group at N8 (Figure 9).
On the other hand, compounds 6D and 34 were the most active compounds against
intracellular amastigotes of T. cruzi, with IC50 values of 3.78 (0.31) and 4.24 (0.29) µM,
respectively. Interestingly, both of these compounds contain a phenyl group at C8 and a
small substituent at N9, which seems to be crucial for displaying activity against amastigote
forms (Figure 9). Our docking study further suggested that Pf HGXPRT and TcHGPRT
enzymes could be the main potential targets of those compounds. Thus, two novel, purine-
based chemotypes with potent activities against either P. falciparum or T. cruzi have been
identified, and could be further optimized to eventually generate potent and diverse
antiparasitic drugs.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14070638/s1: Table S1: Primary screening against P. falciparum; Table S2: Primary screen-
ing and IC50 values of non-progressed compounds against T. cruzi; Table S3: Information on the
P. falciparum and T. cruzi enzymes used for the docking study; Supporting information: 1H-NMR,
13C-NMR, and HRMS data for compounds 1B, 2A, 3F, 4, 4M, 13H, 13ME, 21, 22, 23, 27, 28, 29, MJ-1,
MJ-5, MJ-7, MJ-8, MJ-11, MJ-16, MJ-17, MJ-24, 6g, and 6D.
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